Cytokinetics Inc’s recent filing unveils that its Director Kaye Edward M. MD unloaded Company’s shares for reported $0.34 million on Sep 02 ’25. In the deal valued at $50.00 per share,6,756 shares were sold. As a result of this transaction, Kaye Edward M. MD now holds 23,230 shares worth roughly $1.15 million.
Then, ROBERT HARRINGTON bought 4,300 shares, generating $151,919 in total proceeds.
Before that, Harrington Robert Arthur sold 2,150 shares. Cytokinetics Inc shares valued at $104,640 were divested by the Director at a price of $48.67 per share. As a result of the transaction, Harrington Robert Arthur now holds 20,493 shares, worth roughly $1.02 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock jump 40.45% to $49.62. Over the last five days, the stock has gained 34.07%. Cytokinetics Inc shares have fallen nearly -10.64% since the year began. Nevertheless, the stocks have risen 5.48% over the past one year. While a 52-week high of $59.39 was reached on 01/27/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 46.28, which if violated will result in even more drops to 42.94. On the upside, there is a resistance level at 51.59. A further resistance level may holdings at 53.56.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-08-15, dropping by -0.6 million shares to a total of 15.33 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 15.93 million shares. There was a decline of -3.95%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
